Biotech Archives - Page 16 of 795

2 minute read

Why Microbot Medical Stock Is Up

June 3, 11:36 AM

Microbot Medical shares are trading higher Monday after the company announced that it has received FDA approval to proceed with its human clinical trial as part of its Investigational Device Exemption (IDE) application for its LIBERTY Endovascular Robotic Surgical System.

MBOT

2 minute read

Obesity Data From Structure Therapeutics Shows Potential For Weight Loss Drug Candidate

By Vandana Singh

June 3, 11:11 AM

Structure Therapeutics announces Phase 2a results for GSBR-1290, showing significant weight loss in obesity study.

GPCR

2 minute read

Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients

By Vandana Singh

June 3, 10:27 AM

Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3 trials are now underway for melanoma and non-small cell lung cancer.

MRK

2 minute read

Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward

By Vandana Singh

June 3, 9:53 AM

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022 decision dismissing similar cases, potentially increasing GSK's liability.

GSK

1 minute read

Precigen Announces Study Data For PRGN-2012 For Recurrent Respiratory Papillomatosis Patients; Phase 1/2 Pivotal Study Met Primary And Efficacy Endpoints

By Benzinga Newsdesk

June 3, 9:31 AM

– Phase 1/2 pivotal study met the primary safety and efficacy endpoints –– 51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012;

PGEN

1 minute read

Kite, A Gilead Company Presents New Data On Yescarta For Relapsed/Refractory Central Nervous System Lymphoma

By Benzinga Newsdesk

June 3, 9:11 AM

-- At Median Follow-Up of 24.2 Months, No Additional Risks of Adverse Events Related to Yescarta Were Observed ---- Findings Also Suggest Efficacy Trend with Median Progression-Free Survival and Durability of Response of

GILD

1 minute read

Evaxion Presents Validating Immune Data From Ongoing Phase 2 Trial With AI-Designed EVX-01 Vaccine At The ASCO Annual Meeting 2024

By Benzinga Newsdesk

June 3, 8:47 AM

Evaxion's AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patients Findings further confirm and validate the precision and predictive power of

EVAX

1 minute read

Enlivex Receives Regulatory Authorization For The Initiation Of A Placebo-Controlled Phase I/II Trial Evaluating Allocetra In Up To 46 Patients With Thumb Osteoarthritis

By Benzinga Newsdesk

June 3, 8:43 AM

First study of AllocetraTM in thumb osteoarthritis, a debilitating disease that affects millions of people in the U.S., and has no FDA-approved therapy Third study of AllocetraTM in osteoarthritis, following

ENLV

1 minute read

Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential As A Precision Medicine For Cancer

By Benzinga Newsdesk

June 3, 8:38 AM

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE

CYCC

1 minute read

Scorpius And Beyond Imagination Announce Partnership To Utilize Autonomous AI-Powered Humanoid Robots For American Biomanufacturing

By Benzinga Newsdesk

June 3, 8:22 AM

Collaboration aims to enhance biomanufacturing reliability, scalability and efficiency Autonomous humanoids designed to complement human labor andenhance productivity through 24/7 operational capabilitiesBeyond's

SCPX